Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
GIP and GLP-1 Pathways The compound is studied because it interacts with both GIP and GLP-1 receptor pathways, making it different from GLP-1-only research compounds
In this 52-week trial of 1,698 people with type 2 diabetes whose blood sugar wasn't adequately controlled on Metformin, orforglipron outperformed oral semaglutide on every primary and secondary endpoint, including A1C reduction and weight loss, with improvements visible as early as four weeks
Also known as GGG Tri-agonist, GLP-1/GIP/glucagon tri-agonist, or LY3437943, this injectable medication is similar to existing weight loss medications like tirzepatide and semaglutide but has increased efficacy
However, not all patients feel comfortable using a syringe, so the development of oral medications or pills is seen as an important step in expanding access to treatment
US$ 20.43
US$ 25.37
US$ 26.84
.png.jpg)
US$ 26.11
US$ 27.04
US$ 24.75
US$ 20.02
US$ 22.71
